<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386721</url>
  </required_header>
  <id_info>
    <org_study_id>BP40234</org_study_id>
    <secondary_id>2017-003182-94</secondary_id>
    <nct_id>NCT03386721</nct_id>
  </id_info>
  <brief_title>Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor&#xD;
      activity of simlukafusp alfa in combination with atezolizumab in participants with advanced&#xD;
      and/or metastatic solid tumors. Currently the focus is on patients with Head and Neck,&#xD;
      oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">December 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start, up to approximately 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Control According to RECIST Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to RECIST Version 1.1</measure>
    <time_frame>From first occurrence of documented CR or PR up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to RECIST Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to death due to any cause (up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline up to end of the study (up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Programmed Death-Ligand 1 (PD-L1) Status According to Immunohistochemical Methods</measure>
    <time_frame>Baseline, Cycle 3 Day 8, Day 1 of Cycle 9 onwards up to end of the study (up to approximately 2 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of Cluster of Differentiation (CD) 8 Positive (CD8+) Cells According to Immunohistochemical Methods</measure>
    <time_frame>Day1 of Cycles 1, 2, 3, 6, and 9 onwards up to end of the study (up to approximately 2 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of Cluster of Differentiation 3 Negative (CD3-) Perforin Positive Cells According to Immunohistochemical Methods</measure>
    <time_frame>Day1 of Cycles 1, 2, 3, 6, and 9 onwards up to end of the study (up to approximately 2 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of PD-L1 According to Immunohistochemical Methods</measure>
    <time_frame>Baseline, Cycle 3 Day 8, Day 1 of Cycle 9 onwards up to end of the study (up to approximately 2 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers</condition>
  <arm_group>
    <arm_group_label>Cohort A (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D Arm I (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.&#xD;
Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D Arm 2 (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.&#xD;
Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D Arm 3 (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E Arm I (Part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E Arm 2 (Part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.&#xD;
Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.&#xD;
Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort K (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort L (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort M (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort N (Part III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simlukafusp alfa</intervention_name>
    <description>simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.</description>
    <arm_group_label>Cohort A (Part I)</arm_group_label>
    <arm_group_label>Cohort B (Part I)</arm_group_label>
    <arm_group_label>Cohort C (Part I)</arm_group_label>
    <arm_group_label>Cohort D Arm 2 (Part I)</arm_group_label>
    <arm_group_label>Cohort D Arm I (Part I)</arm_group_label>
    <arm_group_label>Cohort E Arm 2 (Part II)</arm_group_label>
    <arm_group_label>Cohort E Arm I (Part II)</arm_group_label>
    <arm_group_label>Cohort F (Part I)</arm_group_label>
    <arm_group_label>Cohort G (Part III)</arm_group_label>
    <arm_group_label>Cohort H (Part III)</arm_group_label>
    <arm_group_label>Cohort I (Part III)</arm_group_label>
    <arm_group_label>Cohort J (Part III)</arm_group_label>
    <arm_group_label>Cohort K (Part III)</arm_group_label>
    <arm_group_label>Cohort L (Part III)</arm_group_label>
    <arm_group_label>Cohort M (Part III)</arm_group_label>
    <arm_group_label>Cohort N (Part III)</arm_group_label>
    <other_name>RO6874281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody</intervention_name>
    <description>Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.</description>
    <arm_group_label>Cohort A (Part I)</arm_group_label>
    <arm_group_label>Cohort B (Part I)</arm_group_label>
    <arm_group_label>Cohort C (Part I)</arm_group_label>
    <arm_group_label>Cohort D Arm 2 (Part I)</arm_group_label>
    <arm_group_label>Cohort D Arm I (Part I)</arm_group_label>
    <arm_group_label>Cohort E Arm 2 (Part II)</arm_group_label>
    <arm_group_label>Cohort E Arm I (Part II)</arm_group_label>
    <arm_group_label>Cohort F (Part I)</arm_group_label>
    <arm_group_label>Cohort G (Part III)</arm_group_label>
    <arm_group_label>Cohort H (Part III)</arm_group_label>
    <arm_group_label>Cohort I (Part III)</arm_group_label>
    <arm_group_label>Cohort J (Part III)</arm_group_label>
    <arm_group_label>Cohort K (Part III)</arm_group_label>
    <arm_group_label>Cohort L (Part III)</arm_group_label>
    <arm_group_label>Cohort M (Part III)</arm_group_label>
    <arm_group_label>Cohort N (Part III)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Single-agent treatment administered as per approved protocol.</description>
    <arm_group_label>Cohort D Arm 3 (Part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Single-agent treatment administered as per approved protocol.</description>
    <arm_group_label>Cohort D Arm 3 (Part I)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have progressed on at least one previous regimen of anticancer&#xD;
             therapy (chemotherapy, mutation targeted therapy, and/or CPI therapy)&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST Version 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 or Karnofsky&#xD;
             Performance Score greater than or equal to (&gt;=) 70&#xD;
&#xD;
          -  Life expectancy of &gt;=12 weeks&#xD;
&#xD;
          -  Confirmed at least one tumor lesion with location accessible to safely biopsy per&#xD;
             clinical judgment of the treating physician.&#xD;
&#xD;
        Biopsies are not applicable to participants in Cohorts G, H, K, and L presenting with a&#xD;
        single target lesion and absence of any non-target lesion.&#xD;
&#xD;
          -  Consent to provide an archival tumor tissue sample (if available, applicable to all&#xD;
             participants)&#xD;
&#xD;
          -  Willingness to undergo baseline and on-treatment tumor biopsies for pharmacodynamics&#xD;
             (PD) biomarker analysis (biopsies are optional for Cohort A)&#xD;
&#xD;
          -  Adequate cardiovascular function as defined in the study protocol&#xD;
&#xD;
          -  AEs related to any previous radiotherapy, chemotherapy, or surgical procedure must&#xD;
             have resolved to Grade less than or equal to (&lt;=) 1, except alopecia (any grade) and&#xD;
             Grade 2 peripheral neuropathy&#xD;
&#xD;
          -  Adequate haematological, liver, and renal functions.&#xD;
&#xD;
          -  Participants with unilateral pleural effusion (indications other than NSCLC) are&#xD;
             eligible if they fulfill both of the following:&#xD;
&#xD;
               1. NYHA Class 1&#xD;
&#xD;
               2. Forced expiratory volume 1 (FEV1) and forced vital capacity (FVC) &gt;70% of&#xD;
                  predicted value; participants with lung metastases should present with DLCO &gt;60%&#xD;
                  of predicted value.&#xD;
&#xD;
          -  Participants with Gilbert's syndrome will be eligible for the study&#xD;
&#xD;
          -  Participants must have had confirmed diagnosis of recurrent or metastatic squamous&#xD;
             cell carcinoma head and neck, or esophageal cancer or metastatic, persistent or&#xD;
             recurrent squamous cervical cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or untreated central nervous system (CNS) metastases&#xD;
&#xD;
          -  History of treated asymptomatic CNS metastases as described in the protocol&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for &gt;=2 weeks before enrollment&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  An active second malignancy&#xD;
&#xD;
          -  Penetrating tumor infiltration&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results&#xD;
&#xD;
          -  Episode of significant cardiovascular/cerebrovascular acute disease within 6 months&#xD;
             before study treatment administration&#xD;
&#xD;
          -  History of significant vascular disease (for example, aortic aneurysm, aortic&#xD;
             dissection)&#xD;
&#xD;
          -  Active or uncontrolled infections&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) or Active Hepatitis A, B, C, D or E infection&#xD;
             (HAV/HBV/HCV/HDV/HEV).&#xD;
&#xD;
          -  Severe infection within 4 weeks before study treatment administration including, but&#xD;
             not limited to, hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia.&#xD;
&#xD;
          -  History of chronic liver disease or evidence of hepatic cirrhosis&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit informed consent&#xD;
&#xD;
          -  History of, active or suspicion of autoimmune disease&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced),&#xD;
             organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia,&#xD;
             etc.), or evidence of active pneumonitis on screening chest computed tomography (CT)&#xD;
             scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted&#xD;
&#xD;
          -  Bilateral pleural effusion confirmed by X-ray&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that give reasonable suspicion of a disease or condition that would&#xD;
             contraindicate the use of an investigational drug&#xD;
&#xD;
          -  Concurrent therapy with any other investigational drug&#xD;
&#xD;
          -  Immunomodulating agents as described in study protocol&#xD;
&#xD;
          -  Chronic use of steroids&#xD;
&#xD;
          -  Last dose with any cytostatic treatments &lt; 28 days before study treatment&#xD;
             administration&#xD;
&#xD;
          -  Radiotherapy within the last 4 weeks before start of study treatment administration,&#xD;
             with the exception of limited field palliative radiotherapy&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or at&#xD;
             any time during the study and 5 months after the last dose of atezolizumab&#xD;
&#xD;
          -  Major surgery or significant traumatic injury &lt;28 days before study treatment&#xD;
             administration (excluding fine needle biopsies) or if wound healing has not completed&#xD;
             after surgery or anticipation of the need for major surgery during study treatment&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of the simlukafusp alfa drug product&#xD;
             or atezolizumab drug product&#xD;
&#xD;
          -  Severe dyspnea at rest or requiring supplementary oxygen therapy Locally curative&#xD;
             options are available for participant's disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Timone Adultes; Oncologie Medicale Et Usp</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM; Medecine B3</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Innere Klinik (Tumorforschung)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Oncology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital; Clinical Oncology</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N.Burdenko Main Military Clinical Hospital; Oncology Dept</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital; National University Cancer Institute, Singapore (NCIS)</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra Madrid; Servicio de Oncología</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Madrid. Centro Integral Oncologico Clara Campal; CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung Uni Hospital; Dept of Hematology and Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; Dept of Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adana Baskent University Hospital; Medical Oncology</name>
      <address>
        <city>Adana</city>
        <zip>01120</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty; Medical Oncology Department</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpaşa-Cerrahpaşa Medical Faculty; Medikal Onkoloji Departmani</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>İzmir Medical Park; Onkoloji</name>
      <address>
        <city>Izmır</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology</name>
      <address>
        <city>Kadiköy</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts</name>
      <address>
        <city>London</city>
        <zip>EC1M6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 - 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

